US Patent 10464964 Galactoside inhibitor of galectins
Patent 10464964 was granted and assigned to Galecto Biotech on November, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+468 characters)
Article
Patent abstract
An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Edits on 3 Oct, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Fredrik Zetterberg0
Hakon Leffler0
Priya Verma0
Richard Johnsson0
Thomas Brimert0
Ulf Nilsson0
Edits on 31 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
104649640
Date of Patent
November 5, 2019
0Patent Application Number
155358370
Date Filed
January 14, 2016
0Patent Citations Received
Patent Primary Examiner
Edits on 9 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 29 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10464964 Galactoside inhibitor of galectins
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10464964
Date of patent
November 5, 2019
Patent application number
15535837
Date Filed
January 14, 2016
Patent primary examiner
Find more entities like US Patent 10464964 Galactoside inhibitor of galectins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.